Rising evidentiary standards, pricing pressure and policy changes are redefining what it takes for pharmaceutical products to succeed. Pharmaceutical companies must rethink how R&D decisions are made, ensuring that clinical trial designs reflect the kind of evidence required for access and optimal reimbursement. Unfortunately, in too many companies, clinical development…
More than 22,000 pharmaceutical jobs were cut in 2025 as companies brace for a $300 billion patent cliff. But the real story is not workforce reduction. It’s the reshaping of competition, value and decision-making across the entire market. Pharmaceutical companies must move beyond cost-cutting and incremental innovation by embedding evidence,…
Across the globe, medical device and diagnostic companies are experiencing new levels of price resistance and competitive pressure. No one wants to spend more than they already do – unless they’re given a compelling reason. The only counter to that pressure is compelling evidence of differentiated value. Once considered nice-to-have,…
In the past, product approval meant demonstrating safety and efficacy to regulatory bodies in discrete countries—with a placebo comparator. Today companies must anticipate a changing reimbursement, adoption, and policy environment. The need to make population-based decision-makers aware of the value the new product brings while tailoring evidence to the specific…
Traditionally, launch sequencing has been guided by market size, eligible patient population, and the likelihood of securing market access and adoption. While these criteria are still important, they’re no longer sufficient. Growing budget constraints, more stringent evidence requirements, and the rise of external reference pricing and transparency are forcing pharma…
Across the globe, pharma companies are experiencing new levels of price resistance and competitive pressure. No one wants to spend more than they already do – unless they’re given a compelling reason. The only counter to that pressure is compelling evidence of differentiated value. Once considered nice-to-have, real-world evidence (RWE)…
